Mapping the Brain While on Psychedelics with Manesh Girn
Psychedelic neuroscientist Manesh Girn talks about his research into neuroimaging of the brain while subjected to psychedelic states and more.
Similar Posts
“Taking the leap” on Plant Medicines and Psilocybin with Formed NHL Enforcer Riley Cote
In today’s Psychedelic Spotlight episode, we see David Flores and…
Interview with Dr. Erica Zelfand
This week on the Psychedelic Spotlight podcast, we’re chatting with Dr. Erica Zelfand. She is a family doctor specializing in integrative and functional family medicine. She’s also a ketamine prescriber, facilitator of therapeutic experiences, and a medical writer and public speaker.
![New Players, New Studies & Financial Results [MindMed, CMPS, NUMI, TRUFF & WESA]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-136-600x338.jpeg)
New Players, New Studies & Financial Results [MindMed, CMPS, NUMI, TRUFF & WESA]
Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode.
Timestamps:
0:00 – Intro
0:18 – FDA clears researchers to test MDMA on themselves
1:55 – MindMed (MMED / MNMD) announces Q1 Financials
4:30 – Compass Pathways (CMPS) announces Q1 Financials
6:56 – Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health
8:17 – Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’
9:31 – Wesana Health Holdings (WESA) begins trading on the CSE
Link to the FDA clearing researchers to test MDMA on themselves:
https://www.marijuanamoment.net/fda-clears-researchers-to-study-mdma-use-by-therapists-being-trained-in-psychedelic-medicine/
Link to Mindmed’s Q1 2021 Financial report and business highlights:
https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html
Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html
Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health:
https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application
Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’:
https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/
Link to Wesana Health Holdings (WESA):
https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse
Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #CMPS
Numinus Acquires Novamind: What Does This Mean for the Psychedelic Industry? | NUMI, NM
Numinus Acquiring Novamind in First Major Psychedelics Merger
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Back to Numinus
This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).
The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.
If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.
#Numinus #NovaMind #psychedelicStocks
Why Are Psychedelic Stocks Falling? (MindMed, Atai, Cybin, FieldTrip, Compass Pathways)
What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), atai Life Sciences (atai: NASDAQ), Field Trip (FTRP: TSE) ( FTRP: NASDAQ), Cybin (CYBN: NYSE) and many more have experienced a decline in stock prices. So in this episode, we’ll be discussing the reasons behind this and whether we are ignoring some red flags.
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #FieldTrip #PsychedelicStocks
Interview with Joe Moore, Founder & CEO of Psychedelics Today
In this episode, Joe discusses the current landscape of the industry, his thoughts on its general direction, and why we need to defund the DEA to really progress the movement overall.